253 related articles for article (PubMed ID: 11832530)
1. Expression of p53 and prognosis in children with malignant gliomas.
Pollack IF; Finkelstein SD; Woods J; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Boyett JM; Finlay JL; Sposto R;
N Engl J Med; 2002 Feb; 346(6):420-7. PubMed ID: 11832530
[TBL] [Abstract][Full Text] [Related]
2. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
[TBL] [Abstract][Full Text] [Related]
3. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the TP53 gene in human gliomas.
Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
[TBL] [Abstract][Full Text] [Related]
5. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
Pollack IF; Hamilton RL; Sobol RW; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL
J Clin Oncol; 2006 Jul; 24(21):3431-7. PubMed ID: 16849758
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
7. Ethnicity delineates different genetic pathways in malignant glioma.
Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
[TBL] [Abstract][Full Text] [Related]
8. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.
Bredel M; Pollack IF; Hamilton RL; James CD
Clin Cancer Res; 1999 Jul; 5(7):1786-92. PubMed ID: 10430083
[TBL] [Abstract][Full Text] [Related]
10. PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
Rasheed BK; Stenzel TT; McLendon RE; Parsons R; Friedman AH; Friedman HS; Bigner DD; Bigner SH
Cancer Res; 1997 Oct; 57(19):4187-90. PubMed ID: 9331072
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
12. [Mutations of p53 gene in 41 cases of human brain gliomas].
Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
14. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.
Fouladi M; Hunt DL; Pollack IF; Dueckers G; Burger PC; Becker LE; Yates AJ; Gilles FH; Davis RL; Boyett JM; Finlay JL
Cancer; 2003 Sep; 98(6):1243-52. PubMed ID: 12973849
[TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of the functional p53 status in glioma cells.
Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
[TBL] [Abstract][Full Text] [Related]
16. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.
Jin W; Xu X; Yang T; Hua Z
Chin Med J (Engl); 2000 Jul; 113(7):662-6. PubMed ID: 11776043
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas.
Mueller W; Lass U; Wellmann S; Kunitz F; von Deimling A
Acta Neuropathol; 2005 Mar; 109(3):314-20. PubMed ID: 15668788
[TBL] [Abstract][Full Text] [Related]
18. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
19. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix.
Waggoner SE; Anderson SM; Luce MC; Takahashi H; Boyd J
Gynecol Oncol; 1996 Mar; 60(3):339-44. PubMed ID: 8774636
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]